Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 80

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 80
---
Beth has the right of first refusal for a period of six (6) months after the Closing Date (October 21, 2024) to participate in each and every future public and private equity and debt offerings of ours, or any successor to or any subsidiary of ours in any U.S. stock exchange during such six (6) month period, and (b) if we, within twelve (12) months after the Closing Date, effect a sale of any securities with a party brought “over-the-wall” by WallachBeth in connection with the October 2024 Offerings, we will pay to WallachBeth the same cash discount and will issue to WallachBeth placement agent warrants exercisable for such number of shares equal to 3.0% of the securities issued in such offering upon the completion of such transaction.

Pursuant to the October 2024 Purchase Agreement, we agreed to file a resale registration statement on Form S-1 to register the resale of the October 2024 Common Warrant Shares as soon as practicable (and in any event within 45 calendar days following the date of the October 2024 Purchase Agreement), and to use commercially reasonable efforts to have such registration statement declared effective by the SEC and to keep such registration statement effective at all times until the October 2024 Investors no longer owns any October 2024 Common Warrants or October 2024 Common Warrant Shares. On November 27, 2024, we filed the December 2024 Registration Statement (Registration No. 333-283521), registering the resale of the October 2024 Common Warrant Shares, which was subsequently declared effective by the SEC on December 6, 2024. The December 2024 Registration Statement also registers the resale of the shares of Common Stock issuable upon exercise of the October 2024 PA Warrants.

Terms of the October 2024 Common Warrants

The October 2024 Common Warrants will be exercisable commencing on the effective date of stockholder approval of the exercise of the October 2024 Common Warrants and issuance of the October 2024 Common Warrant Shares upon exercise of the October 2024 Common Warrants, which approval was obtained on December 20, 2024, and will expire on the fifth anniversary of such date. The October 2024 Common Warrants have an exercise price of $1.50 per share.

If at any time after the six-month anniversary of the Closing Date a registration statement registering the issuance of the